Apoptosis May Be an Early Event of Progestin Therapy for Endometrial Hyperplasia

This publication has 28 references indexed in Scilit:

• Down-Regulation of Bcl-2 Is a Potential Marker of the Efficacy of Progestin Therapy in the Treatment of Endometrial Hyperplasia
  Gynecologic Oncology, 1999
• Progestin alone as primary treatment of endometrial carcinoma in premenopausal women
  Cancer, 1997
• bcl-2 Expression in Endometrial Hyperplasia and Carcinoma
  Gynecologic Oncology, 1996
• Changes in levels of mRNAs of transforming growth factor (TGF)-β1, -β2, -β3, TGF-β type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium
  The Journal of Steroid Biochemistry and Molecular Biology, 1996
• Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivity
  International Journal of Gynecologic Cancer, 1996
• Apoptosis in the Pathogenesis and Treatment of Disease
  Science, 1995
• Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium
  New England Journal of Medicine, 1981
• Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy
  International Journal of Cancer, 1979
• Progestin therapy in endometrial hyperplasia
  Gynecologic Oncology, 1974
• THE EFFECTS OF PROGESTATIONAL AGENTS ON HYPERPLASIA AND CARCINOMA IN SITU OF THE ENDOMETRIUM. A 10-YEAR FOLLOW-UP
  Obstetrical & Gynecological Survey, 1971